|
gptkbp:instanceOf
|
antiviral drug
|
|
gptkbp:administeredBy
|
gptkb:hospital
intravenous infusion
|
|
gptkbp:approvalYear
|
2020
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
J05AB16
|
|
gptkbp:brand
|
gptkb:Veklury
|
|
gptkbp:CASNumber
|
1809249-37-3
|
|
gptkbp:chemicalFormula
|
C27H35N6O8P
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to remdesivir
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:India
gptkb:Japan
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:discoveredBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:drugClass
|
nucleotide
|
|
gptkbp:eliminationHalfLife
|
1 hour (parent), 25 hours (metabolite)
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:firstSynthesized
|
2009
|
|
gptkbp:form
|
solution for injection
lyophilized powder
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Remdesivir
|
|
gptkbp:indication
|
hospitalized COVID-19 patients
|
|
gptkbp:KEGGID
|
D11472
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:mechanismOfAction
|
RNA polymerase inhibitor
|
|
gptkbp:MedlinePlusID
|
a620033
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
602.6 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:B2
N
not recommended
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:PubChem_CID
|
121304016
DB14761
58828033
CHEMBL2016761
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:routesOfElimination
|
urine
feces
|
|
gptkbp:sideEffect
|
nausea
elevated liver enzymes
allergic reactions
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:UNII
|
O3J8G9O825
|
|
gptkbp:usedFor
|
gptkb:COVID-19
gptkb:Ebola_virus_disease
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Gilead_Sciences
gptkb:Gilead
|
|
gptkbp:bfsLayer
|
5
|